source
- Taiho and Cullinan’s zipalertinib shows progression‑free survival benefit in Phase 3 NSCLC trialTaiho Pharmaceutical and Cullinan Therapeutics reported that their EGFR inhibitor zipalertinib, combined with chemotherapy, significantly extended progression‑free survival for patients with advanc…
- Zealand Pharma sells rights to rare blood cancer drug rusfertide for up to $100MZealand Pharma entered a royalty purchase and sale agreement with Royalty Pharma, receiving $50 million upfront and the possibility of an additional $50 million after one year. In exchange, Zealan…